KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.96

Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study.

Luca Mastrantoni, Antonio Vitale, Jacopo Russo, Giulia Giordano, Emanuele Vita, Massimo Di Maio, Diana Giannarelli, Giampaolo Tortora, Gennaro Daniele, Emilio Bria

J Natl Cancer Inst djag241

PMID42477876
PMCID-
DOI10.1093/jnci/djag241
发表日期2026-07-21
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
图像/No. at risk 复核:未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: In biomarker-selected non-small cell lung cancer (NSCLC) targeted therapies often produce substantial improvements in survival outcomes. We conducted a systematic review of phase III randomized controlled trials (RCTs) in oncogene-driven NSCLC to evaluate the concordance between design assumptions and observed treatment effects. METHODS: MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched for phase III RCTs published between January 1, 2005, and February 1, 2025, enrolling patients with metastatic or locally advanced, biomarker-selected NSCLC, comparing targeted agents versus standard regimens in a superiority design. Hazard ratios (HRs) for progression-free survival were considered. Statistical analyses included meta-analyses with meta-regression; retrodesign analysis of power, type S error, and exaggeration ratios; design-outcome concordance; and restricted mean survival time (RMST). RESULTS: 1987 records were screened, and 45 studies included. Progression-free survival was the primary outcome in all RCTs. Median expected HR was 0.64 (IQR 0.61-0.67). Pooled observed HR was 0.47 (95% CI 0.40-0.54), studies with higher standard errors were associated with larger treatment effects (P<.001). Statistically significant results were reported in 38 (84%) RCTs. Under original assumptions, median retrodesign power was 0.78 (IQR 0.72-0.88), and using the observed HR, median power was 1.00 (IQR 0.98-1.00). Pooled observed-to-expected HR ratio was 0.76 (95%CI 0.66-0.87). In Bayesian analyses, 17 (41%) trials had <1% probability of exceeding planned HR. Proportional hazards (PH) assumption was violated in 8 trials (19%). Pooled HR/RMST ratio was 1.40 (95% CI 1.29-1.52). CONCLUSIONS: Our work supports reporting retrodesign metrics, the minimal clinically important difference alongside the anticipated effect size, and systematic inclusion of RMST.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。